Neil Kumar, Ph.D.

Neil Kumar, Ph.D.

DirectoratBridgeBio Pharma· In proxies 2021–2025

Pay in FY2024+28% from the year before · BridgeBio Pharma stock -32.0% the same year

Neil Kumar, Ph.D. was paid $15.6M in FY2024 (Dec), up 28%. BridgeBio Pharma stock fell 32.0% that year.

Pay$100 in the stock at the end of FY20 → $39
Pay is from the Summary Compensation Table of each BridgeBio Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Maze TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. BridgeBio Oncology TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  3. BridgeBio PharmaPublic company · 5 yr
    • Chief Executive Officer2021 – Present · 5 yrStock in role +2%
  4. Maze Therapeutics, Inc.Public company · Less than 1 yr
    • Director2026 – Present · Less than 1 yrNo stock prices for these years
  5. GondolaBio, LLCPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  6. LianBioPublic company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Maze TherapeuticsDirector · -1 yr on the boardIndependent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?